Sarepta Therapeutics
SRPT
114 hedge funds and large institutions have $321M invested in Sarepta Therapeutics in 2015 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 37 reducing their positions, and 20 closing their positions.
293% more call options, than puts
Call options by funds: $37.3M | Put options by funds: $9.47M
3% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 37
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 120 → 114 (-6)
10% less capital invested
Capital invested by funds: $355M → $321M (-$34.4M)
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
PointState Capital
New York
|
+$6.66M |
| 2 |
HM
HealthCor Management
New York
|
+$6.17M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.39M |
| 4 |
Renaissance Technologies
New York
|
+$3.1M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$3.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$8.1M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$5.66M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$5.39M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$5.05M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$2.54M |
SRPT Hedge Fund Activity: Q1 2015 in Review
114 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2015, worth a combined $321M — down 9.7% from $355M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of SRPT and 14 opened new positions — a net loss of 6 holders — while 37 trimmed existing stakes and 38 added.
The largest buyer was PointState Capital, adding an estimated $6.66M. The largest seller was Perceptive Advisors, cutting an estimated $8.1M.
- 114 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2015, down from 120 in Q4 2014.
- Funds reported $321M of Sarepta Therapeutics stock for Q1 2015, down 9.7% quarter-over-quarter.
- 14 funds opened new Sarepta Therapeutics positions in Q1 2015 and 20 closed out, a net change of -6 holders.
- The largest Sarepta Therapeutics buyer in Q1 2015 was PointState Capital, an estimated $6.66M added.
- The largest Sarepta Therapeutics seller in Q1 2015 was Perceptive Advisors, an estimated $8.1M sold.
Based on aggregated 13F filings for Q1 2015.